Jin Ng, PhD

Super excited (!!) to share our recent publication from @sutherlandlab.bsky.social @wehi-research.bsky.social in @cp-cancercell.bsky.social www.cell.com/cancer-cell/... Personal thank you to patients & Cancer Council Victoria @iaslc.bsky.social The CASS Foundation for supporting this research

Very grateful to be invited to present at this @togaanz.bsky.social webinar! Will highlight some of the exciting translational research we've been doing in @sutherlandlab.bsky.social at @wehi-research.bsky.social

TOGA@togaanz.bsky.social

Connect research with real-world impact. Translational research plays an important role in moving scientific discoveries from the laboratory into clinical practice. But progress takes collaboration. Join TOGA for Translational Research Insights, a webinar bringing researchers together to share

dlvr.itγδ T cells BiTE back at small cell lung cancerIn this issue of Cancer Cell, Ng et al. characterize and leverage cytotoxic γδ T cells in small cell lung cancer to overcome unsuccessful checkpoint blockade immunotherapy. Engaging Vδ2+ cells with a bispecific T cell engager (BiTE) bypasses the challenge of low MHC-I expression and ineffective CD8+ T cells.

Thank you David Hamilton, Mohindar Karunakaran, and Seth Coffelt for this thoughtful Preview on our work!

Cancer Cell@cp-cancercell.bsky.social

γδ T cells BiTE back at small cell lung cancer

Jin Ng, PhD reposted

Cancer Cell

@cp-cancercell.bsky.social

γδ T cells modulate anti-tumor immunity in small cell lung cancer

dlvr.itγδ T cells modulate anti-tumor immunity in small cell lung cancerNg et al. show that γδ T cells infiltrate SCLC and have cancer-fighting abilities. These cells can be harnessed through multiple therapeutics to kill SCLC, including through MHC-independent recognition mechanisms via BTN2A1. Notably, γδ T cell infiltration is clinically relevant in SCLC, with high levels predictive of improved outcomes with αPD-L1.

Excited to share our pre-print "γδ T cells modulate anti-tumor immunity in small cell lung cancer" from @sutherlandlab.bsky.social doi.org/10.1101/2025... We demonstrate that γδ T cells are potentially valuable targets for SCLC therapy, especially in a MHC-I low setting. 🧵1/8

Surprisingly, we observed tarlatamab-independent killing of SCLC by γδ T, but not CD8 T cells. An effect further enhanced by treatment with FDA-approved zoledronate. 🧵6/8

Using both autologous and allogenic patient-derived co-cultures, we validated these findings and describe clinically actionable strategies to harness γδ T cells for SCLC therapy. 🧵7/8

We extended this observation through analysis of IMpower133. Uncovered association between γδ T cell gene signatures and improved outcomes + ICB. Patients that had high γδ T gene signatures were also found in SCLC-A/N/P subtypes. 🧵4/8

Given clinical efficacy of tarlatamab, we explored whether γδ T cells could be effectively targeted to SCLC using tarlatamab. Indeed, we found that γδ T cells are as effective as CD8 T cells at tarlatamab-redirected killing of SCLC. 🧵5/8

Using single cell approaches, we show that γδ T cells are present in the SCLC tumor microenvironment and are poised to exert anti-tumor activity. γδ T cells show high cytotoxic signature compared to co-located NK and CD8 T cells. 🧵2/8